{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T17:40:10Z","timestamp":1750527610398,"version":"3.41.0"},"reference-count":42,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Cancer J"],"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Smoldering multiple myeloma (MM) is a clonal plasma cell disorder characterized by excess marrow involvement and immunoglobulin production. It is the precursor of MM, differing by the lack of end-organ damage. Smoldering MM encompasses a heterogeneous group of patients, with a median risk of progression to active disease of 50% in the first 5 years. Until recently, the standard of care would dictate observation off therapy until the development of end-organ damage. The recognition of high-risk and ultrahigh-risk subgroups of smoldering MM, with more likely evolution to MM, has led to earlier initiation of therapy in the disease course. Ongoing studies to define the ideal timing and patient population are underway, as well as identification of which agents would be of greatest benefit, as the armamentarium for MM continues to grow.<\/jats:p>","DOI":"10.1097\/ppo.0000000000000528","type":"journal-article","created":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T21:33:01Z","timestamp":1621459981000},"page":"185-189","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Smoldering Myeloma Treatment"],"prefix":"10.1097","volume":"27","author":[{"given":"Mateo","family":"Mejia Saldarriaga","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriana","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"bib1-20250621","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1056\/NEJM198006123022405","article-title":"Smoldering multiple myeloma","volume":"302","year":"1980","journal-title":"N Engl J Med"},{"key":"bib2-20250621","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1182\/blood.V56.3.521.521","article-title":"Localized and indolent myeloma","volume":"56","year":"1980","journal-title":"Blood"},{"key":"bib3-20250621","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1056\/NEJMoa070389","article-title":"Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma","volume":"356","year":"2007","journal-title":"N Engl J Med"},{"key":"bib4-20250621","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","year":"2014","journal-title":"Lancet Oncol"},{"key":"bib5-20250621","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.3109\/10428194.2013.764419","article-title":"Modeling progression risk for smoldering multiple myeloma: results from a prospective clinical study","volume":"54","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"bib6-20250621","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1182\/blood-2007-08-108357","article-title":"Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma","volume":"111","year":"2008","journal-title":"Blood"},{"key":"bib7-20250621","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/leu.2012.296","article-title":"Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma","volume":"27","year":"2013","journal-title":"Leukemia"},{"key":"bib8-20250621","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41408-018-0077-4","article-title":"Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria","volume":"8","year":"2018","journal-title":"Blood Cancer J"},{"key":"bib9-20250621","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41408-020-00366-3","article-title":"International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)","volume":"10","year":"2020","journal-title":"Blood Cancer J"},{"key":"bib10-20250621","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/leu.2012.237","article-title":"High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myeloma","volume":"27","year":"2013","journal-title":"Leukemia"},{"key":"bib11-20250621","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/leu.2016.205","article-title":"Quantification of circulating clonal plasma cells via multiparametric flow cytometry identifies patients with smoldering multiple myeloma at high risk of progression","volume":"31","year":"2017","journal-title":"Leukemia"},{"key":"bib12-20250621","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1182\/blood-2007-05-088443","article-title":"New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells","volume":"110","year":"2007","journal-title":"Blood"},{"key":"bib13-20250621","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1001\/jamaoncol.2019.4659","article-title":"Moving from cancer burden to cancer genomics for smoldering myeloma: a review","volume":"6","year":"2020","journal-title":"JAMA Oncol"},{"key":"bib14-20250621","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1080\/10428194.2019.1620948","article-title":"Smoldering multiple myeloma: the role of different scoring systems in identifying high-risk patients in real-life practice","volume":"60","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"bib15-20250621","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1200\/JCO.2009.25.5356","article-title":"Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma","volume":"28","year":"2010","journal-title":"J Clin Oncol"},{"key":"bib16-20250621","doi-asserted-by":"crossref","first-page":"e364","DOI":"10.1038\/bcj.2015.87","article-title":"Positron emission tomography\u2013computed tomography in the diagnostic evaluation of smoldering multiple myeloma: identification of patients needing therapy","volume":"5","year":"2015","journal-title":"Blood Cancer J"},{"key":"bib17-20250621","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/leu.2015.291","article-title":"18F-FDG PET\/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease","volume":"30","year":"2016","journal-title":"Leukemia"},{"key":"bib18-20250621","doi-asserted-by":"crossref","first-page":"9054","DOI":"10.4081\/hr.2020.9054","article-title":"The molecular pathogenesis of multiple myeloma","volume":"12","year":"2020","journal-title":"Hematol Rep"},{"key":"bib19-20250621","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1038\/s41375-019-0634-2","article-title":"Cytogenetic subclone formation and evolution in progressive smoldering multiple myeloma","volume":"34","year":"2020","journal-title":"Leukemia"},{"key":"bib20-20250621","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1038\/s41467-018-05058-y","article-title":"Genomic patterns of progression in smoldering multiple myeloma","volume":"9","year":"2018","journal-title":"Nat Commun"},{"key":"bib21-20250621","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1200\/JCO.20.00437","article-title":"Genomic profiling of smoldering multiple myeloma identifies patients at a high risk of disease progression","volume":"38","year":"2020","journal-title":"J Clin Oncol"},{"key":"bib24-20250621","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1182\/blood-2015-10-662320","article-title":"Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under lendex: a longitudinal analysis","volume":"127","year":"2016","journal-title":"Blood"},{"key":"bib25-20250621","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1007\/s00277-019-03648-4","article-title":"PD-L1, LAG3, and HLA-DR are increasingly expressed during smoldering myeloma progression","volume":"98","year":"2019","journal-title":"Ann Hematol"},{"key":"bib26-20250621","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1046\/j.1365-2141.2003.04654.x","article-title":"Smoldering multiple myeloma: natural history and recognition of an evolving type","volume":"123","year":"2003","journal-title":"Br J Haematol"},{"key":"bib27-20250621","doi-asserted-by":"crossref","first-page":"e454","DOI":"10.1038\/bcj.2016.65","article-title":"Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma","volume":"6","year":"2016","journal-title":"Blood Cancer J"},{"key":"bib28-20250621","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1038\/s41375-018-0013-4","article-title":"Evolving M-protein pattern in patients with smoldering multiple myeloma: impact on early progression","volume":"32","year":"2018","journal-title":"Leukemia"},{"key":"bib29-20250621","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41408-018-0144-x","article-title":"Evolving changes in M-protein and hemoglobin as predictors for progression of smoldering multiple myeloma","volume":"8","year":"2018","journal-title":"Blood Cancer J"},{"key":"bib30-20250621","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1600-0609.1993.tb00148.x","article-title":"Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I\u2014a randomized study. Myeloma Group of Western Sweden","volume":"50","year":"1993","journal-title":"Eur J Haematol"},{"key":"bib31-20250621","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1054\/bjoc.1999.1087","article-title":"Long-term survival of stage I multiple myeloma given chemotherapy just after diagnosis or at progression of the disease: a multicentre randomized study. Cooperative Group of Study and Treatment of Multiple Myeloma","volume":"82","year":"2000","journal-title":"Br J Cancer"},{"key":"bib32-20250621","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1002\/cncr.23783","article-title":"A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma","volume":"113","year":"2008","journal-title":"Cancer"},{"key":"bib33-20250621","doi-asserted-by":"crossref","first-page":"771","DOI":"10.3109\/10428194.2011.553000","article-title":"Pamidronate versus observation in asymptomatic myeloma: final results with long-term follow-up of a randomized study","volume":"52","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"bib34-20250621","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/leu.2012.236","article-title":"A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma","volume":"27","year":"2013","journal-title":"Leukemia"},{"key":"bib35-20250621","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa1300439","article-title":"Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma","volume":"369","year":"2013","journal-title":"N Engl J Med"},{"key":"bib36-20250621","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1200\/JCO.19.01740","article-title":"Randomized trial of lenalidomide versus observation in smoldering multiple myeloma","volume":"38","year":"2020","journal-title":"J Clin Oncol"},{"key":"bib37-20250621","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1038\/s41375-020-0718-z","article-title":"Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS)","volume":"34","year":"2020","journal-title":"Leukemia"},{"key":"bib38-20250621","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1001\/jamaoncol.2015.2010","article-title":"Treatment with carfilzomib-lenalidomide-dexamethasone with lenalidomide extension in patients with smoldering or newly diagnosed multiple myeloma","volume":"1","year":"2015","journal-title":"JAMA Oncol"},{"key":"bib39-20250621","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1182\/blood-2019-125204","article-title":"Curative strategy (GEM-CESAR) for high-risk smoldering myeloma (SMM): carfilzomib, lenalidomide and dexamethasone (KRd) as induction followed by HDT-ASCT, consolidation with KRd and maintenance with Rd","volume":"134","year":"2019","journal-title":"Blood"},{"key":"bib40-20250621","first-page":"35","article-title":"Aggressive Smoldering Curative Approach Evaluating Novel Therapies (ASCENT): a phase 2 trial of induction, consolidation and maintenance in subjects with high risk smoldering multiple myeloma (SMM): initial analysis of safety data","volume":"136","year":"2020","journal-title":"Blood"},{"key":"bib41-20250621","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/bjh.15384","article-title":"Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study","volume":"182","year":"2018","journal-title":"Br J Haematol"},{"key":"bib42-20250621","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.1182\/bloodadvances.2019000300","article-title":"A pilot study of pembrolizumab in smoldering myeloma: report of the clinical, immune, and genomic analysis","volume":"3","year":"2019","journal-title":"Blood Adv"},{"key":"bib43-20250621","doi-asserted-by":"crossref","first-page":"3772","DOI":"10.1158\/1078-0432.CCR-18-3470","article-title":"Randomized, double-blind, placebo-controlled, multicenter study of siltuximab in high-risk smoldering multiple myeloma","volume":"25","year":"2019","journal-title":"Clin Cancer Res"},{"key":"bib44-20250621","doi-asserted-by":"crossref","first-page":"183267","DOI":"10.1001\/jamaoncol.2018.3267","article-title":"Assessment of safety and immunogenicity of PVX-410 vaccine with or without lenalidomide in patients with smoldering multiple myeloma: a nonrandomized clinical trial","volume":"4","year":"2018","journal-title":"JAMA Oncol"}],"container-title":["The Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PPO.0000000000000528","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T17:00:33Z","timestamp":1750525233000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PPO.0000000000000528"}},"subtitle":["Who, What, and When"],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/ppo.0000000000000528","relation":{},"ISSN":["1540-336X","1528-9117"],"issn-type":[{"type":"electronic","value":"1540-336X"},{"type":"print","value":"1528-9117"}],"subject":[],"published":{"date-parts":[[2021,5]]}}}